Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know

Summit Therapeutics PLC (SMMT) closed the last trading session at $28.02, gaining 61.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of$ 37.38 indicates a 33.4% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $5.71. While the lowest estimate of$ 30 indicates a 7.1% increase from the current price level, the most optimistic an ...